TIL Latest News, Press Relases and Analysis

All

Press Releases

2 months ago - By: Instil Bio

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

2 months ago - By: Instil Bio

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

2 months ago - By: The Motley Fool

Instil Bio Posts Wider Loss in Q2

2 months ago - By: Instil Bio

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Instil Bio

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

4 months ago - By: Zacks Investment Research

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

3 months ago - By: Instil Bio

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

3 months ago - By: Instil Bio

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

4 months ago - By: Benzinga - Mentions: CNC GNTA SBFM SNGX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

4 months ago - By: Instil Bio

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

4 months ago - By: Instil Bio

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

4 months ago - By: Yahoo Finance - Mentions: VZ AMZN WMT EPD ...

Mark Cuban Wants You To Stop Saving Money (And Do This Instead)

5 months ago - By: Instil Bio - Mentions: ALNY

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

5 months ago - By: Instil Bio

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

5 months ago - By: Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

5 months ago - By: Benzinga - Mentions: TLPH FGEN MLTX ANL ...

12 Health Care Stocks Moving In Monday's After-Market Session

5 months ago - By: Zacks Investment Research - Mentions: MRK SMMT BNTX

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

5 months ago - By: Instil Bio

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

5 months ago - By: Instil Bio

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

5 months ago - By: Instil Bio

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

5 months ago - By: Instil Bio

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

5 months ago - By: Zacks Investment Research

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

5 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

5 months ago - By: Instil Bio

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

5 months ago - By: Instil Bio

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

5 months ago - By: Instil Bio

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

5 months ago - By: Instil Bio

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

6 months ago - By: Instil Bio

INSTIL BIO INC (TIL) Stock News

TIL Latest News, Press Relases and Analysis

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio Posts Wider Loss in Q2

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Mark Cuban Wants You To Stop Saving Money (And Do This Instead)

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Are You Looking for a Top Momentum Pick? Why Instil Bio, Inc. (TIL) is a Great Choice

12 Health Care Stocks Moving In Monday's After-Market Session

Summit Therapeutics Stock Nosedives on Mixed NSCLC Study Results

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update